Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆

[1]  K. Hemminki,et al.  Age-specific risk of incident prostate cancer and risk of death from prostate cancer defined by the number of affected family members. , 2010, European urology.

[2]  A Jakubowska,et al.  An inherited NBN mutation is associated with poor prognosis prostate cancer , 2012, British Journal of Cancer.

[3]  K. Offit,et al.  BRCA Mutations and Risk of Prostate Cancer in Ashkenazi Jews , 2004, Clinical Cancer Research.

[4]  J. Trachtenberg,et al.  The impact of a BRCA2 mutation on mortality from screen-detected prostate cancer , 2014, British Journal of Cancer.

[5]  J. Stanford,et al.  Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer , 2007, British Journal of Cancer.

[6]  W. Chung,et al.  Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers , 2017, JAMA.

[7]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[8]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[9]  D. Horsman,et al.  Cancer variation associated with the position of the mutation in the BRCA2 gene , 2004, Familial Cancer.

[10]  D. Easton,et al.  BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients , 2011, British Journal of Cancer.

[11]  Á. Carracedo,et al.  BRCA1 mutations do not increase prostate cancer risk: Results from a meta‐analysis including new data , 2011, The Prostate.

[12]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[13]  D. Steinemann,et al.  Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores , 2017, Journal of Clinical Oncology.

[14]  T. Rebbeck,et al.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. , 2002, Journal of the National Cancer Institute.

[15]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[16]  A. Jakubowska,et al.  BRCA1 mutations and prostate cancer in Poland , 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[17]  K. D. Sørensen,et al.  Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci , 2018, Nature Genetics.

[18]  M. Nilbert,et al.  Increased risk of male cancer and identification of a potential prostate cancer cluster region in BRCA2 , 2016, Acta oncologica.

[19]  Harry J de Koning,et al.  Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.

[20]  L. Kiemeney,et al.  Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study , 2014, European urology.

[21]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[22]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[23]  F. Hamdy,et al.  Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study , 2017, BMJ Open.

[24]  P. Scardino,et al.  Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer , 2010, Clinical Cancer Research.

[25]  D. Easton,et al.  Germline BRCA1 mutations increase prostate cancer risk , 2012, British Journal of Cancer.

[26]  Ilir Agalliu,et al.  Associations of High-Grade Prostate Cancer with BRCA1 and BRCA2 Founder Mutations , 2009, Clinical Cancer Research.

[27]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[28]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2011, Familial Cancer.

[29]  D. Easton,et al.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. , 2001, American journal of human genetics.

[30]  E. Friedman,et al.  Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers , 2015, Breast Cancer Research and Treatment.

[31]  J. Jeter,et al.  The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis , 2022 .

[32]  T. H. van der Kwast,et al.  A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. , 2019, European urology.